Recent Quotes (30 days)

You have no recent quotes
chg | %

Medicure Inc  

(Public, CVE:MPH)   Watch this stock  
Find more results for CVE:MPH.H
+0.05 (0.95%)
May 26 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 5.26 - 5.38
52 week 2.12 - 7.29
Open 5.27
Vol / Avg. 7,248.00/52,399.00
Mkt cap 77.91M
P/E 37.09
Div/yield     -
EPS 0.14
Shares 14.67M
Beta 0.46
Inst. own 4%
Aug 9, 2016
Q2 2016 Medicure Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
May 12, 2016
Q1 2016 Medicure Inc Earnings Call
May 12, 2016
Q1 2016 Medicure Inc Earnings Call
May 11, 2016
Q1 2016 Medicure Inc Earnings Release
May 11, 2016
Q1 2016 Medicure Inc Earnings Call
Mar 31, 2016
Q4 2015 Medicure Inc Earnings Call
Mar 30, 2016
Q4 2015 Medicure Inc Earnings Release

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin 13.04% 7.56%
Operating margin 20.12% 24.67%
EBITD margin - 24.51%
Return on average assets 16.15% 12.00%
Return on average equity 66.00% 606.12%
Employees 18 -
CDP Score - -


2-1250 Waverley St
+1-204-4877412 (Phone)
+1-204-4889823 (Fax)

Website links


Medicure Inc. (Medicure) is a pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics. The Company's primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban hydrochloride) owned by its subsidiary, Medicure International, Inc. and distributed in the United States and its territories through the Company's United States subsidiary, Medicure Pharma, Inc. The Company is also engaged in the clinical development of TARDOXAL for neurological disorders. The Company's primary, non-AGGRASTAT research and development activity is TARDOXAL for the treatment of Tardive Dyskinesia (TD). The Company has completed Phase IIa stage of development for TARDOXAL. The Company is also developing Transdermal AGGRASTAT, a cure for acute cardiology. Transdermal AGGRASTAT is in preclinical-stage of development.

Officers and directors

Albert D. Friesen Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 68
James F. Kinley Chief Financial Officer, Secretary
Age: 37
Brent Fawkes Director
Age: 45
Gerald P. McDole Independent Director
Age: 75
Arnold Naimark Independent Director
Age: 81
Peter Quick Independent Director
Age: 59